| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MDM4 |
| Uniprot No | O15151 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 381-490aa |
| 氨基酸序列 | ENSKLFDPCNSVEFLDLAHSSESQETISSMGEQLDNLSEQRTDTENMEDC QNLLKPCSLCEKRPRDGNIIHGRTGHLVTCFHCARRLKKAGASCPICKKE IQLVIKVFIA |
| 预测分子量 | 38 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MDM4重组蛋白的示例参考文献(注：以下内容为模拟示例，非真实文献)：
---
1. **标题**：*Structural characterization of recombinant human MDM4 and its binding mechanism to p53*
**作者**：Zhang Y, et al.
**摘要**：本研究通过大肠杆菌表达系统纯化了重组人MDM4蛋白，并利用X射线晶体学解析其结构，揭示了MDM4与p53反式激活结构域的关键结合位点，为靶向MDM4的抗癌药物设计提供了结构基础。
---
2. **标题**：*Recombinant MDM4 protein enhances p53 degradation in vitro and modulates cellular stress response*
**作者**：Martinez R, et al.
**摘要**：通过昆虫细胞体系表达并纯化功能性MDM4重组蛋白，证明其与MDM2协同促进p53泛素化及蛋白酶体降解，进一步阐明了MDM4在DNA损伤应答中的调控作用。
---
3. **标题**：*Development of a high-throughput screening assay using recombinant MDM4 for small molecule inhibitors*
**作者**：Chen L, et al.
**摘要**：构建了基于重组MDM4蛋白的荧光偏振筛选平台，成功筛选出多个可阻断MDM4-p53相互作用的小分子化合物，为恢复p53活性的癌症治疗策略提供新候选分子。
---
4. **标题**：*Functional analysis of MDM4 isoforms: Insights from recombinant protein expression in mammalian cells*
**作者**：Johnson M, et al.
**摘要**：通过哺乳动物细胞表达系统制备不同剪接变体的重组MDM4蛋白，发现特定异构体对p53的抑制作用存在差异，提示其在肿瘤发生中的潜在选择性调控机制。
---
如需真实文献，建议通过PubMed或Web of Science以“MDM4 recombinant protein”“MDMX expression and purification”等关键词检索近年研究。
**Background of MDM4 Recombinant Protein**
MDM4 (Mouse Double Minute 4), also known as MDMX, is a critical regulatory protein within the p53 tumor suppressor network. Functioning as a homolog of MDM2. MDM4 binds directly to p53 and inhibits its transcriptional activity, thereby modulating cellular responses to stress, DNA damage, and oncogenic signaling. Unlike MDM2. which primarily promotes p53 degradation via ubiquitination, MDM4 acts as a non-degradative suppressor, forming heterodimers with MDM2 to enhance its E3 ligase activity. This interplay fine-tunes p53 levels and activity, ensuring balanced control over cell cycle arrest, apoptosis, and genome stability.
Structurally, MDM4 contains an N-terminal p53-binding domain, a central zinc finger motif, and a C-terminal RING domain essential for MDM2 interaction. Dysregulation of MDM4 is implicated in cancer pathogenesis; its overexpression in tumors (e.g., breast, lung, colorectal) correlates with p53 inactivation, chemoresistance, and poor prognosis. Conversely, loss of MDM4 in normal tissues triggers p53 hyperactivation, leading to developmental defects or tissue damage, highlighting its dual role as both an oncogene and a guardian of homeostasis.
Recombinant MDM4 protein is engineered using expression systems (e.g., *E. coli*, mammalian cells*) to produce functional, purified protein for research. It enables studies on MDM4-p53/MDM2 interactions, screening of small-molecule inhibitors (e.g., ALRN-6924), and structural analyses (e.g., X-ray crystallography). Its applications extend to understanding resistance mechanisms in TP53 wild-type cancers and developing targeted therapies to reactivate p53. As a research tool, MDM4 recombinant protein is vital for dissecting its role in oncogenesis and therapeutic contexts.
×
